Chlorquinaldol API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Chlorquinaldol API 72-80-0?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Chlorquinaldol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Chlorquinaldol
- Synonyms:
- 2-methyl-5,7-dichloro-8-hydroxyquinoline , 5,7-dichloro-2-methyl-8-hydroxyquinoline , 5,7-dichloro-2-methyl-8-quinolinol , 5,7-dichloro-8-hydroxy-2-methylquinoline , 5,7-dichloro-8-hydroxyquinaldine , 5,7-dichloro-8-quinaldinol , Chlorchinaldol , Chlorquinaldolum , Clorquinaldol
- Cas Number:
- 72-80-0
- DrugBank number:
- DB13306
- Unique Ingredient Identifier:
- D6VHC87LLS
General Description:
Chlorquinaldol, identified by CAS number 72-80-0, is a notable compound with significant therapeutic applications. Chlorquinaldol was used historically as a topical antiseptic under the trade name Sterosan. It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.
Indications:
This drug is primarily indicated for: Chlorquinaldol was used historically as a topical antiseptic agent for skin infections. It maintains use in European countries as a combination vaginal tablet with promestriene for use in the treatment of vaginal infections. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Chlorquinaldol undergoes metabolic processing primarily in: 98% of drug is converted to the sulfate form and renally excreted. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Chlorquinaldol are crucial for its therapeutic efficacy: There is a high degree of variability in the extent of absorption of topically applied chorquinaldol preparations. It is reported to be between 4.2 and 23.5% of the applied dose. This is quite low compared to orally administered preparations which displayed 67.6% absorption in the same study. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Route of Elimination:
The elimination of Chlorquinaldol from the body primarily occurs through: Chlorquinadol is primarily excreted in the urine as the sulfate form. About 2% is excreted as the parent drug. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Pharmacodynamics:
Chlorquinaldol exerts its therapeutic effects through: Chlorquinaldol is bacteriocidal in both gram positive and gram negative bacteria. It is more effective in targeting gram positive bacteria, particularly staphylococci. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Chlorquinaldol functions by: The mechanism by which Chlorquinaldol exerts it's bacteriocidal effect is unknown. 8-hydroxyquinolines are known to be bidentate chelators of several metal ions which act as critical enzyme cofactors. However, the addition of exogenous metal ions does not appear to alter the minimum inhibitory concentration for mycobacterium tuberculosis suggesting that the primary mechanism does not rely on chelation. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Chlorquinaldol belongs to the class of organic compounds known as chloroquinolines. These are compounds containing a quinoline moiety, which carries one or more chlorine atoms, classified under the direct parent group Chloroquinolines. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Quinolines and derivatives class, specifically within the Haloquinolines subclass.
Categories:
Chlorquinaldol is categorized under the following therapeutic classes: Anti-Infective Agents, Anti-Infective Agents, Local, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Antiseptics and Disinfectants, Cell-mediated Immunity, Chloroquinolinols, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Hydroxyquinoline Derivatives, Hydroxyquinolines, Increased Histamine Release, Quinoline Derivatives, Quinolines, Standardized Chemical Allergen, Throat Preparations. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Chlorquinaldol include:
- Melting Point: 108-112
Chlorquinaldol is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
